The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of studies testing the compound vs. placebo on top of standard-of-care (SOC) maintenance therapy in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD).

Multiple sclerosis (MS) is a degenerative and inflammatory condition of the central nervous system (CNS) that impacts more than 2.5 million individuals globally. Interleukin-33 (IL-33) is an immunoregulatory cytokine that has shown a mild inhibitory effect on experimental autoimmune encephalomyelitis (EAE), which serves as a mouse model for MS. However, its clinical application is limited by unfavorable pharmacokinetics and associated toxicity.

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with IL-33-blocking monoclonal antibody itepekimab failed in chronic obstructive pulmonary disease (COPD). The Tarrytown, N.Y.-based firm’s shares (NASDAQ:REGN) closed May 30 at $490.28, down $115.11, or 19%. Partner Sanofi SA, of Paris, saw its stock (NASDAQ:SNY) dip somewhat, too, and ended at $49.37, down $2.98. Cantor analyst Carter Gould opined that the latest news “all but [ruled] out a path forward short of a new study” with the compound.

Why cancer? The mechanisms that drive and maintain tumorigenesis are still a mystery. This is a play with different actors who have different roles in several contexts. One of these scenarios is represented by genetic and epigenetic conditions that determine the early trajectories of cancer cells. In addition, different mechanisms will control phenotypes and states that can take one or another direction toward cancer.

Researchers from Astrazeneca plc have presented a novel adeno-associated virus (AAV)-delivered human (h)IL-33 neutralizing scFv-based protein construct at the 2023 World Congress on Basic and Clinical Pharmacology.

Researchers from Cincinnati Children’s Hospital Medical Center have published data from a study that aimed to investigate the role of interleukin-33 (IL-33) in cardiac remodeling after acute kidney injury (AKI).

The growth of some pancreatic cancers is fueled by fungus-induced production of the cytokine IL-33, and the progression of such tumors could be slowed down by treatment with antifungals or genetic deletion of IL-33, researchers reported in the February 3, 2022, online issue of Cancer Cell.

Parasitic worms, or helminths, are a major global health issue. At the same time, "parasites have been a prolific area of biomedical research to emerge," De'Broski Herbert told his audience at the 2021 annual meeting of the American Association of Immunologists.